Carmell Therapeutics Corp... (CTCX)
0.20
0.01 (2.77%)
At close: Mar 07, 2025, 3:55 PM
Company Description
Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging.
Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing.
The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.
Carmell Therapeutics Corporation
| Country | United States |
| IPO Date | Sep 23, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Rajiv Sarman Shukla |
Contact Details
Address: 2403 Sidney Street Pittsburgh, Pennsylvania United States | |
| Website | https://www.carmellrx.com |
Stock Details
| Ticker Symbol | CTCX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001842939 |
| CUSIP Number | 142922103 |
| ISIN Number | US1429221039 |
| Employer ID | 00-0000000 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Rajiv Sarman Shukla | Chief Executive Officer & Executive Chairman |
| Bryan J. Cassaday | Chief Financial Officer |
| Dr. James Burgess M.D. | Founder |
| Dr. Lee Weiss Ph.D. | Founder |
| Dr. Phil Campbell Ph.D. | Founder and Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 10, 2025 | 424B3 | Filing |
| Mar 10, 2025 | 8-K | Current Report |
| Mar 06, 2025 | 424B3 | Filing |
| Mar 05, 2025 | 8-K | Current Report |
| Feb 13, 2025 | 424B3 | Filing |
| Feb 10, 2025 | DEF 14A | Filing |
| Feb 10, 2025 | DEF 14A | Filing |
| Feb 07, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 03, 2025 | S-3 | Filing |
| Jan 31, 2025 | PRE 14A | Filing |